Graybug Vision (GRAY) Competitors $1.52 +0.01 (+0.66%) As of 04/29/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GRAY vs. ACXP, CTXR, BTAI, MYNZ, CARM, HCWB, GELS, TLPH, AIMD, and GNPXShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include Acurx Pharmaceuticals (ACXP), Citius Pharmaceuticals (CTXR), BioXcel Therapeutics (BTAI), Mainz Biomed (MYNZ), Carisma Therapeutics (CARM), HCW Biologics (HCWB), Gelteq (GELS), Talphera (TLPH), Ainos (AIMD), and Genprex (GNPX). These companies are all part of the "pharmaceutical preparations" industry. Graybug Vision vs. Acurx Pharmaceuticals Citius Pharmaceuticals BioXcel Therapeutics Mainz Biomed Carisma Therapeutics HCW Biologics Gelteq Talphera Ainos Genprex Acurx Pharmaceuticals (NASDAQ:ACXP) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Which has better earnings & valuation, ACXP or GRAY? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$0.87-0.49Graybug VisionN/AN/A-$35.60M-$24.23-0.06 Does the media favor ACXP or GRAY? In the previous week, Acurx Pharmaceuticals had 3 more articles in the media than Graybug Vision. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 0 mentions for Graybug Vision. Graybug Vision's average media sentiment score of 1.10 beat Acurx Pharmaceuticals' score of 0.62 indicating that Graybug Vision is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Positive Graybug Vision Positive Do analysts rate ACXP or GRAY? Acurx Pharmaceuticals presently has a consensus price target of $12.00, indicating a potential upside of 2,690.70%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Acurx Pharmaceuticals is more favorable than Graybug Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ACXP or GRAY? Acurx Pharmaceuticals has a beta of -1.36, suggesting that its share price is 236% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Does the MarketBeat Community favor ACXP or GRAY? Acurx Pharmaceuticals and Graybug Vision both received 16 outperform votes by MarketBeat users. However, 94.12% of users gave Acurx Pharmaceuticals an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1694.12% Underperform Votes15.88%Graybug VisionOutperform Votes1650.00% Underperform Votes1650.00% Is ACXP or GRAY more profitable? Graybug Vision's return on equity of -77.61% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Graybug Vision N/A -77.61%-71.34% Do institutionals and insiders believe in ACXP or GRAY? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 29.6% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAcurx Pharmaceuticals beats Graybug Vision on 9 of the 14 factors compared between the two stocks. Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.39M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.887.4422.4818.48Price / SalesN/A242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.916.516.774.25Net Income-$35.60M$143.21M$3.22B$248.23M7 Day Performance-0.65%1.98%1.48%0.89%1 Month Performance-20.42%6.89%3.99%3.53%1 Year Performance-74.50%-2.52%16.15%5.08% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$1.52+0.7%N/A-73.5%$2.39MN/A-0.8827Positive NewsHigh Trading VolumeACXPAcurx Pharmaceuticals2.6765 of 5 stars$0.42+3.6%$12.00+2,764.0%-80.9%$9.39MN/A-0.383News CoverageCTXRCitius Pharmaceuticals2.5832 of 5 stars$0.84-0.6%$54.50+6,357.3%-95.9%$9.03MN/A0.0020Positive NewsBTAIBioXcel Therapeutics4.4409 of 5 stars$1.96+4.8%$42.60+2,073.5%-95.4%$8.94M$2.27M-0.0690Upcoming EarningsPositive NewsMYNZMainz Biomed2.9731 of 5 stars$3.70+4.8%$14.00+278.4%-90.3%$8.58M$893,991.00-0.0630Short Interest ↓Gap UpHigh Trading VolumeCARMCarisma Therapeutics3.4421 of 5 stars$0.20-9.7%$1.93+843.6%-87.8%$8.53M$19.63M-0.1320Upcoming EarningsShort Interest ↓Positive NewsHCWBHCW Biologics1.0035 of 5 stars$7.58+9.8%N/A-85.6%$8.51M$2.57M-7.5840Gap DownGELSGelteqN/A$2.33+22.6%N/AN/A$8.50MN/A0.00N/ALockup ExpirationGap DownTLPHTalphera2.1274 of 5 stars$0.48-1.3%$4.33+803.5%-52.4%$8.20M$281,000.00-0.7019Short Interest ↑AIMDAinos0.6896 of 5 stars$0.54-1.7%N/A-48.0%$8.10M$20,729.00-0.3240GNPXGenprex4.0188 of 5 stars$0.29+1.8%$10.00+3,348.3%-87.2%$8.09MN/A0.0020News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies ACXP Competitors CTXR Competitors BTAI Competitors MYNZ Competitors CARM Competitors HCWB Competitors GELS Competitors TLPH Competitors AIMD Competitors GNPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRAY) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRAY Stock Free GRAY Stock Alerts